[Pregnancy termination in the second trimester with vaginally administered dinoprostone followed by intravenous sulprostone, for the indication 'foetal congenital defects'; results of a retrospective study].
Willems
F E
FE
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced / Q000379:methods*; D015232:Dinoprostone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage; D016595:Misoprostol / Q000008:administration & dosage; D018457:Placenta, Retained; D011247:Pregnancy
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D015735:Mifepristone; C016767:sulprostone; D015232:Dinoprostone
Zwangerschapsafbreking in het tweede trimester met dinoproston vaginaal gevolgd door sulproston intraveneus, op de indicatie 'foetale congenitale afwijkingen'; resultaten van een retrospectieve studie.